Korro Bio Entered into a Definitive Merger Agreement with Frequency Therapeutics to Advance RNA Editing Programs
Shots:
- The combined company is expected to have ~$170M in cash, cash equivalents, and marketable securities after estimated transaction expenses & is expected to provide a cash runway through several value-creating milestones and into 2026. The merger is expected to close in Q4’23
- The combined company focuses to accelerate Korro Bio’s portfolio of RNA editing programs & is expected to operate under Korro Bio, Inc. and will trade on Nasdaq under the ticker symbol “KRRO”
- Additionally, Korro Bio continues to expand the lead program for AATD to a clinical trial and plans to submit a regulatory filing in H2’24
Ref: Businesswire | Image: Korro
Related News:- Astellas Signs a License Agreement with Frequency Therapeutics to Develop and Commercialize FX-322 for Hearing Loss
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
